Enalare Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2.5M

  • Investors
  • 4

Enalare General Information

Description

Operator of a biopharmaceutical company intended to provide therapies for patients suffering from acute respiratory conditions. The company's biopharmaceutical platform provides pharmaceutical preparations and medical information for the treatment of opioid addiction, opioid overdose, and opioid dependence, and it also develops agnostic therapeutic breathing stimulants, enabling patients to get treatment for the life-threatening disease of acute respiratory depression.

Contact Information

Website
www.enalare.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 107 Gilbreth Parkway
  • Mullica Hill, NJ 08062
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 107 Gilbreth Parkway
  • Mullica Hill, NJ 08062
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Enalare Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 30-Jan-2025 $2.5M Completed Clinical Trials - Phase 2
4. Early Stage VC 09-Aug-2022 Completed Clinical Trials - Phase 2
3. Grant 01-Jul-2022 Completed Clinical Trials - Phase 2
2. Grant 01-Jul-2022 $2.8M $10M Completed Clinical Trials - Phase 2
1. Seed Round 02-Feb-2021 $10M $10M Completed Startup
To view Enalare’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Enalare Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to provide therapies for patients suffering from acute respiratory cond
Drug Discovery
Mullica Hill, NJ
10 As of 2025

Vancouver, Canada
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Enalare Competitors (60)

One of Enalare’s 60 competitors is viDA Therapeutics, a Venture Capital-Backed company based in Vancouver, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
viDA Therapeutics Venture Capital-Backed Vancouver, Canada
Avalyn Pharma Formerly VC-backed Boston, MA
Rein Therapeutics Formerly VC-backed Austin, TX
Regenerx Formerly VC-backed Rockville, MD
uniQure Formerly VC-backed Amsterdam, Netherlands
You’re viewing 5 of 60 competitors. Get the full list »

Enalare Patents

Enalare Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024357318-A1 Methods and compositions for treating drug overdose Pending 09-Oct-2023
EP-4791375-A1 Methods and compositions for treating drug overdose Pending 09-Oct-2023
US-20250114370-A1 Methods and compositions for treating drug overdose Pending 09-Oct-2023
WO-2025080559-A1 Methods and compositions for treating drug overdose Inactive 09-Oct-2023
EP-4543455-A2 Methods of treating neurological ventilatory insufficiency Pending 24-Jun-2022 A61K31/53
To view Enalare’s complete patent history, request access »

Enalare Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Enalare Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eagle Pharmaceuticals Corporation Minority
Thornapple River Capital Venture Capital Minority
National Institute on Drug Abuse (NIDA) Government
National Institutes of Health Government
To view Enalare’s complete investors history, request access »

Enalare FAQs

  • When was Enalare founded?

    Enalare was founded in 2018.

  • Where is Enalare headquartered?

    Enalare is headquartered in Mullica Hill, NJ.

  • What is the size of Enalare?

    Enalare has 10 total employees.

  • What industry is Enalare in?

    Enalare’s primary industry is Drug Discovery.

  • Is Enalare a private or public company?

    Enalare is a Private company.

  • What is Enalare’s current revenue?

    The current revenue for Enalare is .

  • How much funding has Enalare raised over time?

    Enalare has raised $23.5M.

  • Who are Enalare’s investors?

    Eagle Pharmaceuticals, Thornapple River Capital, National Institute on Drug Abuse (NIDA), and National Institutes of Health have invested in Enalare.

  • Who are Enalare’s competitors?

    viDA Therapeutics, Avalyn Pharma, Rein Therapeutics, Regenerx, and uniQure are some of the 60 competitors of Enalare.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process